CTWM
LGND icon

Cherry Tree Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Cherry Tree Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$1.37K – 681
2025
Q1 		$1.37K Buy
+13
New +$1.47K ﹤0.01% 661

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cherry Tree Wealth Management's LGND Position: Q2 2025 in Review

Cherry Tree Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 13 shares — an estimated $1.37K sold.

Cherry Tree Wealth Management first reported a position in LGND in Q1 2025 and held it in 1 quarter. The position peaked at $1.37K in Q1 2025. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Cherry Tree Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cherry Tree Wealth Management sold 13 Ligand Pharmaceuticals shares in Q2 2025, an estimated $1.37K.
  • Cherry Tree Wealth Management first reported a position in Ligand Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Cherry Tree Wealth Management's Ligand Pharmaceuticals position peaked at $1.37K in Q1 2025.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Cherry Tree Wealth Management's 13F filing for Q2 2025, filed 5 Aug 2025.